---
title: Gentian Diagnostics AS - Disclosure of large shareholding
description: (Oslo, 15 June 2018) Reference is made to the stock exchange notice published by Gentian Diagnostics AS (
---

(Oslo, 15 June 2018) Reference is made to the stock exchange notice published by Gentian Diagnostics AS ("Gentian") earlier today regarding an investment in Gentian by Vatne Equity AS and Norron AB.

Vatne Equity AS will in connection with the investment be allocated 699,814 shares in Gentian in a private placement. Vatne Equity has today also acquired 50,000 shares in Gentian Diagnostics AS at a price of NOK 50 per share. Following the issuance of new shares in connection with the private placement and the share purchase, Vatne Equity AS will hold 1,599,814 shares in Gentian, corresponding to 10.39%% of the outstanding shares.

In addition, Lioness AS, a sister company of Vatne Equity AS, owns 150,000 shares in Gentian, corresponding to 1.07% of the outstanding shares.

Following the issuance of new shares in connection with the private placement and the share purchase, Vatne Equity AS and Lioness AS will together hold 1,749,814 shares in Gentian, corresponding to 11.37% of the outstanding shares.

 

For further information, please contact:

Henrik Krefting, CEO  
(+47) 916 12 279 / Email: [hk@vatnecapital.com](mailto:hk@vatnecapital.com)

 

**MeldingsID:** 453766  
**UtstederID:** GENT-ME  
**Instrument:** GENT-ME  
**Marked:** Merkur Market  
**Kategori:** FLAGGING  
**Informasjonspliktige opplysninger:** Ja  
**Vedlegg: [2018 06 15 Flaggemelding -Vatne Equity AS (1)](https://www.gentian.com/hubfs/2018-06-15-Flaggemelding-Vatne-Equity-AS.pdf)**

### You may also read

[Jul 02, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-disclosure-large-shareholding#)

##### [Gentian Diagnostics: Invitation to presentation of second quarter results](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

Gentian Diagnostics ASA will present its second quarter 2026 results on 9 July 2026 at 09.00 CEST. The..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

[Jun 24, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-disclosure-large-shareholding#)

##### [ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

Amsterdam / Moss, 24 June 2026 ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

[May 29, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-disclosure-large-shareholding#)

##### [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)